Glaxo's Avandia to face possible ban from Korean market
Published: 2010-09-30 07:00:00
Updated: 2010-09-30 07:00:00
The Korea Food and Drug Administration is not ban U.K.-based GlaxoSmithKline (GSK)’s blockbuster anti-diabetes pill “Avandia” but stringent restrictions will make it far harder for doctors to prescribe the safety-troubled diabetes drugs.
The European Medicines Agency took harsher action. Europ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
